SAND2016-12398PE

Understanding Receptor Regulation for Designing, Targeting and Delivering Novel Therapeutics

Adrienne C. Greene, Ph.D.
Sandia National Laboratories
Case Western Reserve University
12/05/2016

UNM BIOLOGY

Berkeley
UNIVERSITY OF CALIFORNIA

Sandia National Laboratories

Understanding Regulatory Mechanisms of Biological Systems

Goal: Understand biological systems for applications-based technologies (therapeutic target design, diagnostic tools, biosensing and/or bioengineering technologies)

Novel and Effective Therapeutics

1. Receptor Signal Regulation





2. Targeted Therapeutic Delivery





Complex Regulation of Cell Signaling

One mechanism by which cells communicate with each other is through direct physical contact

1. Signal Reception



2. Signal Transduction



- Cell signaling is “noisy”
  - A single cell input results in a complex cascade of intracellular responses
  - Typically, there are many simultaneous signal inputs, resulting in highly stochastic cell response

3. Activation of Cell Response



Clustering at a Cell-Cell Interface Regulates Signaling

Receptor-ligand organization (clustering) at a membrane is a mechanism for cells to overcome biological noisy signaling environments and impart a downstream signal appropriately



http://www.bme.columbia.edu/~kam/research/research.htm



Correct
Cell Response



Disrupted
Cell Response

Same # of Signal Inputs!

Mossman, K.D, and Groves, J.T. 2005. *Science*. 18: 1191-3.

Eph Receptor Tyrosine Kinase Signaling

Receptor: EphA2

Ligand: ephrinA1



- Bidirectional signaling
  - Bidirectional signaling
- Overexpressed in aggressive cancers
- Highly overexpressed in MDAMB231 cells: invasive and metastatic breast cancer cells
- *Often expressed in triple negative breast cancers (no ER, PR or Her2)*
  - Key therapeutic target

Kullander, K. and Klein, R. 2002. *Nature Reviews*. 3: 475-86.

Activation of Eph Receptors by ephrin Ligands



Zimmer, M. *et al*. 2003. *Nature Cell Biol* 5(10): 869-78.

- Typical Eph receptor activation assays use:
  - co-cultures
  - soluble ephrin
- Forward EphA2 signaling (and likely clustering) must be important in the context of a membrane
- Need to use membrane-bound ephrin ligand to more accurately understand Eph receptor forward signaling

Linking ephrin Ligands to a Supported Lipid Membrane

Ephrin ligands can be purified and linked to a supported lipid membrane, creating a synthetic mimic of the ephrin-expressing cell



Receptors and Ligands Cluster at the Cell-Membrane Interface



- MDAMB231 cells are seeded onto an ephrinA1 bilayer
- Receptor-ligands undergo higher ordering reorganization at the cell-membrane interface
- High resolution microscopy can be used to probe the importance of spatial organization

Membrane-Bound Ligands Activate Cell Receptors



- Ephrin ligands on a supported membrane activate Eph receptors
  - Causes Eph receptors to be phosphorylated
  - Activates an actomyosin-driven contractility



Salaita, K., *et al*. 2010. *Science*. 327(5971): 1380-5.
Xu, Q., *et al*. 2011. *Biophys J*. 101(11): 2731-9.

EphA2-ephrinA1 Clusters Contain Endocytosis Molecules



- Localization of signaling molecules to ephrinA1 was measured
- Four types of localization were characterized
  - Colocalization
  - Homogenous distribution
  - Anti-localization
  - Ring formation
- Maybe these clusters are important sites of endocytosis?



Greene, AC. and Lord, S. *et al.* 2014. *Biophysical Journal* 106: 2196-205.

Clusters are Likely Sites of Clathrin-Mediated Endocytosis



- Endocytosis is a mechanism to downregulate cell signaling, resensitize cells to signaling, recycle receptors and/or degrade signaling molecules

- Perhaps EphA2-ephrinA1 clusters are large sites of clathrin-mediated endocytosis (CME)

http://www.intechopen.com/books/molecular-regulation-of-endocytosis/endocytosis-of-non-enveloped-dna-viruses

Detecting Changes in EphA2 Endocytosis is Challenging



Problems:

- Non-specific labeling
- Lots of background fluorescence
- Consistency with permeabilization and/or labeling
- Always a high background level of internal EphA2



Developing a Live-Cell Endocytosis Assay

0.5µm Z-slices





- Detect internal ephrinA1 using spinning disc confocal microscopy
- All signal must have come from the bilayer, so high signal to noise!
- Detection of small changes, very quantitative, cleaner/more reproducible assay than antibody staining
- Easy background threshold
- Selects for specific punctate spots using a size threshold



Greene, AC. and Lord, S. *et al.* 2014. *Biophysical Journal* 106: 2196-205.

Trans-Endocytosis of ephrinA1 Requires Clathrin









von Kleist, L. *et al.* 2011. Cell, 146(3): 471-84.

Greene, AC. and Lord, S. *et al.* 2014. *Biophysical Journal* 106: 2196-205.

Trans-Endocytosis of ephrinA1 Requires ADAM10





- ADAM10 is a disintegrin and metalloprotease thought to be responsible for the trans-cleavage of ephrinA1
- ADAM10 is necessary for efficient ephrinA1 endocytosis
  - ADAM10/17 was inhibited with a small molecule





Janes, P. *et al.*. 2009. PLoS Biology 7(10): e1000215.

Greene, AC. and Lord, S. *et al.* 2014. *Biophysical Journal* 106: 2196-205.

Using Diffusion Barriers to Alter Clustering: Creating a "Spatial Mutation"



- Using electron beam lithography, diffusion barriers can be created to restrict receptor-ligand mobility
- This assay allows us to probe the importance of EphA2-ephrinA1 reorganization in the context of downstream signaling



Diffusion Barriers Alter EphA2-ephrinA1 Endocytosis



- Imaged using TIRF microscopy
- Only clustering and reorganization is altered
- Chemical composition remains the same



Greene, AC. and Lord, S. *et al.* 2014. *Biophsyical Journal* 106: 2196-205.

Trans-Endocytosis of ephrinA1 is Altered on Grids





Greene, AC. and Lord, S. *et al.* 2014. *Biophysical Journal* 106: 2196-205.

Recruitment of ADAM10 is Decreased on Grids





Salaita, K. and Nair P. *et al.* 2010. *Science* 327: 1380-5.

Structure and Function of EphA2 Clustering

How does clustering from the micron down to the nanoscale regulate signaling?



Seiradake, E., *et al*. 2010. *Nat Struct Mol Biol* 17(4): 398-402.

Molecular Architecture of EphA2 Clustering



- EphA2 forms large-scale oligomers
  - Both in *cis* with other EphA2 receptors and in *trans* with ephrinA1 ligands

- We need to understand more about Eph molecular structure and clustering and how that alters signaling

Modified from Seiradake, E., *et al*. 2012. *Nat Struct Mol Biol* 20(8): 958-64.

EphA2 Signals in a Ligand-Dependent *and* Independent Manner





- Requires fine-tuning the balance of signaling based upon ligand-dependent and ligand-independent signaling; also context and cell type specific

- How Eph clusters (i.e. the stoichiometry of receptor/ligand binding) also changes this signaling map

Miao, H., and Wang, B. 2012. *Semin Cell Dev Biol* 23(1): 16-25.

Why Do We Care About EphA2 Clustering?



- Drug trial for targeting EphA2 expressing cells (e.g. triple negative breast cancers) failed in the Phase I Trial

- 6 women entered (breast, ovarian, endometrial and colon cancer patients)
  - Trial had disastrous effects; all women withdrew due to adverse affects (hemorrhage, liver disorder, etc.)

Annunziata, CM, *et al*. 2013. *Invest New Drugs* 31(1): 77-84.

What Went Wrong with the Trial?

- Monoclonal anti-EphA2 antibody covalently attached to auristatin (microtubule inhibitor)
  - Likely NOT due to non-specific toxicity of auristatin
- Likely due to the antibody components of the antibody-drug conjugate
- In one patient, it caused pulmonary metastases
- **Maybe the artificial clustering induced by the antibody caused toxicity?**



Clustering Correlates to Disease State

- *The most aggressive cancers have the most tightly clustered EphA2 receptors*



- Invasion potential of these cells only correlates to the EphA2 clustering phenotype

- Tightly clustered EphA2 indicative of more dangerous cancers?
  - Could the antibody-drug target be inducing more EphA2 clustering and causing an increased disease state of the cell?

Lohmuller, T., *et al*. 2013. *Nano Letters,* 13(7): 3059-64.

Genetic Mutation of EphA2 *cis* Clustering







- Disrupting Eph clustering at the nanometer/angstrom scale requires genetic mutations
  - Target the sushi domain of the receptor to disrupt EphA2 *cis* clustering
- To do this in an endogenous context requires genome-editing
- We used CRISPR/Cas9 to permanently introduce two point mutations into the sushi domain resulting in an N-linked glycan in the domain

Confining Clustering to Determine Cluster Structure

- Confine clusters to defined regions and limit ligand density
- Flatten cells using integrin adhesions



Immobile RGD, fluid ephrinA1



Mask designed by Zhongwen Chen

Mutant Clusters are More Dynamic and Transient

Wildtype



Mutant



5μm

- Ligand density can be confined while adhering the cells using photolithography
- Mutants cluster faster and less definitively

Imaged every 10 seconds for 6 minutes

Movies are 5 frames per second

Disrupting EphA2 *cis* Interactions is Necessary for Clustering

Side view of unligated EphA2



Rearrangement of Eph-Eph interactions

Side view of ligated EphA2



Top-down view of unligated EphA2



Top-down view of ligated EphA2



- Sushi domain mediates stable Eph-Eph interactions within the cell
- Micron-scale clustering requires binding to ephrinA1 and a disruption of Eph-Eph interactions

Changing Molecular Clustering Changes Invasion Potential

- Invasion potential measures the ability of a cell to leave a colony [tumor] and migrate through certain barriers; it is the hallmark of metastasis
- EphA2 with the sushi domain mutation is ~25% less invasive than the wildtype



Part 1 Conclusions

- The importance of spatio-mechanical regulation of signaling systems across length scales is becoming increasingly evident
- Understanding spatio-mechanical regulation of Eph receptors will provide insights into the misregulation of EphA2 in disease, particularly cancer
- Alternate strategies for targeting these kinds of receptors can be developed



Understanding Regulatory Mechanisms of Biological Systems

Goal: Understand biological systems for applications-based technologies (therapeutic target design, diagnostic tools, biosensing and/or bioengineering technologies)

Novel and Effective Therapeutics

1. Receptor Signal Regulation





2. Targeted Therapeutic Delivery





Targeted Delivery of CRISPR/Cas9 Therapeutics

Experimental Approaches

CRISPR/Cas9 Toolbox



DNA

Phage



Packaging Therapeutics

Protocell







Testing *in vitro*



Model Organisms



CAM



Mouse



Modeling Approaches

Molecular Level Modeling



Vascular Level Modeling

Organ Level Modeling

Liver



Lung



Optimization





Goal: Targeted Therapeutic Delivery

Burkholderia pseudomallei

- *Burkholderia pseudomallei* is a highly drug resistant, intracellular gram-negative bacterium
- Common in Southeast Asia and Northern Australia
  - 20-50% mortality rate
- Infection is acquired by inoculation, inhalation, and aspiration
- Causes melioidosis
  - Pneumonia
  - Bone pain
  - Abscesses
  - Brainstem encephalitis

- ***Goal: Develop novel treatment strategies***



W. Wiersinga, *et al.*, Nature Reviews Microbiology, 2006, 4: 272-82.

The Life Cycle of *Burkholderia pseudomallei*

- Life cycle involves:
  - Adherence and entry into host cells
  - Phagosome escape
  - Cytosolic replication
  - Actin propelling within the cell
  - Spreading to neighboring cells



W. Wiersinga, *et al.*, Nature Reviews Microbiology, 2006, 4: 272-82.

How to Target Resistant Bacteria

1. Genetically Encode Bacteriophage with CRISPR/Cas9



2. Encapsulate Bacteriophage into Nanoparticles



3. Deliver Bacteriophage to Bacterially-Infected Mammalian Cells



4. Bacteriophage Deliver CRISPR/Cas9 to Intracellular Bacteria

Protocell masks bacteriophage from initiating an immune response

Inhibit Antibiotic Resistant Bacteria Using Bacteriophages

Bacteriophages: Bacteria-Specific Viruses







Lytic Phage

- Fast bacterial killing on own
- Challenging to genetically modify

Lysogenic Phage

- Can exist without killing the bacteria
- Easier to genetically modify to contain CRISPR/Cas9; these phage will carry CRISPR as a “Trojan horse” for resistant pathogens

Goal: *Use Bacteriophage as a Trojan Horse for Delivering CRISPR/Cas9 Therapeutics*

https://phagehuntnz.wordpress.com/2014/05/13/phage-hunt-nz-post-fighting-with-phages/

Environmental Isolation of Bacteriophage

Identify regions of interest to isolate phage based on epidemiology

Incubation

Filtration

Concentration



Sample types:

- Water
- Soil
- Sediment



Samples Collected by Dr. Josh Santarpia

Environmental Isolation of Bacteriophage

- Isolated 2 new bacteriophage against *Burkholderia*
  - Isolated from samples collected in Louisiana (ME) and Arizona (AE)
  - Tested stability; currently purifying high titer stocks
  - Sequencing in progress
  - One is lytic and one appears to be lysogenic

CE-7 + train PATRIC annotation



CE-6 + train PHASTER annotation



Sequencing Done by Dr. Yuriy Fofanov

CRISPR/Cas9 Gene Editing Technology

- CRISPR is a novel targeted gene-editing technology
  - Can introduce point mutations, delete genes, and add genes in specific genomic loci
- The technology uses an RNA-guided endonuclease to introduce a DNA break and relies on cellular DNA repair mechanisms to selectively edit genes



http://www.transomic.com/Products/CRISPR-Genome-Editing.aspx

Building a CRISPR/Cas9 Antimicrobial Library

- Overall Goal: Use CRISPR/Cas as an antimicrobial to target intracellular bacteria using bacteriophage delivery
  - *Disrupt gene expression permanently*

- Target essential (genes required for viability) genes in *Burkholderia*, with no off target effects in humans or other organisms
  - FabH (fatty acid and phospholipid metabolism)
  - Isochorismate (iron uptake)
  - KDOP Synthase (synthesis/degradation of lipo- and polysaccharides)

- *Hypothesis: Using CRISPR/Cas9 to induce a double strand break in essential genes would result in cell death, thus acting as an effective "antibiotic"*

CRISPR Targets Kill *Burkholderia*

- Tested gene targets by directly delivering CRISPR/Cas9 components
  - Cloned sgRNA targets into vector expressing both Cas9 and sgRNA
  - Delivered plasmid encoding CRISPR and Cas9 to bacteria and monitored changes in viability
  - All CRISPR/Cas9 targets result in significant cell death



Putting it All Together: Encoding CRISPR/Cas9 Targets into Bacteriophage

- Next steps:
  - Genetically incorporate CRISPR/Cas system into bacteriophage genomes using molecular biology techniques



I. Yosef, *et al.*, PNAS, 2015, 112(23): 7267-72.

How to Target Resistant Bacteria

- Using protocells, we can package and deliver a variety of therapeutic cargos, including bacteriophage, to specific cell types

1. Genetically Encode Bacteriophage with CRISPR/Cas9



2. Encapsulate Bacteriophage into Nanoparticles



3. Deliver Bacteriophage to Bacterially-Infected Mammalian Cells



4. Bacteriophage Deliver CRISPR/Cas9 to Intracellular Bacteria

Protocell masks bacteriophage from initiating an immune response

Using Protocells to Deliver Therapeutic Cargoes

- Protocells are mesoporous silica nanoparticles (MSNP) that can be *easily* loaded with complex mixtures of cargo molecules (DNA, RNA, small molecules, proteins)
- Protocells have a 100-1000 fold higher capacity than other nanoparticles
- Properties of both the MSNP core and the bilayer shell can be precisely modulated to effect behavior



Image Courtesy of Dr. Eric Carnes

Using Protocells to Deliver Therapeutic Cargoes

- Functionalizing the supported lipid membrane with targeting, self and endolysmotic peptides, the protocells can:
  - Be selectively delivered to specific cell types
  - Escape the lysosome
  - Deliver the therapeutic cargo



Image Courtesy of Dr. Eric Carnes and Dr. Carlee Ashley

Encapsulation of Bacteriophage into Protocells

- Tested encapsulation of bacteriophage
  - Bacteriophage were successfully encapsulated
  - Activity was maintained after release from the nanoparticle!



Phage	Initial Activity (pfu/mL)	Encapsulated Activity (pfu/mg)	Loss of Activity (Log pfu)
PL-4A	5.50E+10	1.05E+08	0.5
PL-4B	1.50E+10	4.00E+07	0.6
CE-6	2.38E+10	1.93E+06	2.0
CE-7	1.50E+10	6.50E+06	1.4

SEM Images: Dr. Eric Carnes

Next Steps

- Using protocells, we can package and deliver a variety of therapeutic cargos, including bacteriophage, to specific cell types

1. Genetically Encode Bacteriophage with CRISPR/Cas9



2. Encapsulate Bacteriophage into Nanoparticles



3. Deliver Bacteriophage to Bacterially-Infected Mammalian Cells

4. Bacteriophage Deliver CRISPR/Cas9 to Intracellular Bacteria



Protocell masks bacteriophage from initiating an immune response

Understanding Biological Systems for Integrated Science Applications

Goal: Understand biological systems for designing targeted therapeutics. We can couple our expertise with protocells and cancer cell biology to design and selectively target/deliver novel, more effective chemotherapies







Mouse Image: Courtesy of Dr. Carlee Ashley

Acknowledgements

Berkeley
UNIVERSITY OF CALIFORNIA

PART 1 (UC Berkeley)

Prof. Jay Groves
Dr. Sam Lord
Prof. David Drubin
Dr. Christa Cortesio
Prof. Ke Xu
Sam Kenny
Dr. Hiroyuki Kai
Dr. Shalini Low-Nam
Dr. Aiwei Tian

University of Oxford
Prof. Yvonne Jones
Prof. Elena Seiradake

Sandia National Laboratories

Sandia National Laboratories is a multi-mission laboratory managed and operated by Sandia Corporation, a wholly owned subsidiary of Lockheed Martin Corporation, for the U.S. Department of Energy's National Nuclear Security Administration under contract DE-AC04-94AL85000.

PART 2 (Sandia National Labs)

Dr. Josh Santarpia
Dr. Eric Carnes
Dr. Carlee Ashley
Dr. Darryl Sasaki
Dr. Steve Branda
Dr. George Bachand
Cathryn Siegrist
Danielle Rivera
Patrick Fleig
Kevin Crown
Marissa Anderson

NDSEG
NATIONAL DEFENSE SCIENCE & ENGINEERING GRADUATE FELLOWSHIP